ST. LOUIS, Nov. 18, 2025 (GLOBE NEWSWIRE) -- BellRing Brands, Inc. (NYSE:BRBR) (“BellRing”), a holding company operating in the global convenient nutrition category, today reported results for the fourth fiscal quarter and fiscal year ended September 30, 2025, provided its 2026 outlook and updated its long-term financial algorithm. Fourth Quarter and Fiscal Year 2025 Highlights: Fourth quarter net sales of $648.2 million, up 16.6% year-over-yearFourth quarter operating profit of $102.2 million, net earnings ...

TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) reported today its operational and financial results for the three and nine months ended September 30, 2025. This press release should be read in conjunction with the Company’s Management Discussion and Analysis (“MD&A”) and interim consolidated financial statements for the nine months ended September 30, 2025, which are available on the Company’s website and at www.sedarplus.ca. Highlights from the third quarter i ...

Financial Performance - Revenue reached $476 million in Q3 2025[7] - Net earnings totaled $367 million[7] - Adjusted net earnings amounted to $281 million[7] - Operating cash flow was $383 million[7] - Gross margin for Q3 2025 increased by 70% compared to Q3 2024[24] - Net earnings increased by 138% from $155 million in Q3 2024 to $367 million in Q3 2025[25] - Adjusted net earnings increased by 84% from $153 million in Q3 2024 to $281 million in Q3 2025[25] - Operating cash flow increased by 51% from $254 million in Q3 2024 to $383 million in Q3 2025[25] Operational Highlights - Salobo produced 67,000 ounces of attributable gold, a 7% increase relative to Q3 2024[13] - Peñasquito produced 2.1 million ounces of attributable silver, a 17% increase relative to Q3 2024[13] Corporate Development - Declared a quarterly dividend of $0.165 per common share, a 6.5% increase relative to the fourth quarterly dividend of 2024[9]

Financial Performance - Core revenue increased by 6% year-over-year to $1112 million[22, 49] - Adjusted EBITDA grew by 7% year-over-year to $219 million, with a margin of 195%[22, 49] - Adjusted diluted EPS increased by 22% year-over-year to $109[22, 49] - Adjusted Free Cash Flow – Unrestricted was $124 million[51] Segment Results - Self-Service Banking revenue grew by 11% year-over-year, with Adjusted EBITDA increasing by 21%[27] - Network segment revenue decreased by 1% year-over-year, but LTM ARPU increased by 2%[36, 67] - ATMaaS revenue grew by 37% year-over-year, with gross profit increasing by 65%[58] 2025 Outlook - The company projects core revenue growth of 3% to 6% in constant currency for fiscal year 2025[74] - The company anticipates total Adjusted EBITDA growth of 7% to 10% in constant currency for fiscal year 2025[74] - The company expects fully diluted EPS (non-GAAP) to grow by 21% to 27% in fiscal year 2025[74] - The company forecasts Adjusted Free Cash Flow – Unrestricted to be between $260 million and $300 million[74]

Core Insights - TerrAscend Corp reported net revenue of $65.1 million for Q3 2025, showing stability compared to $65.0 million in Q2 2025 and $65.2 million in Q3 2024 [6][7][10] - The gross profit margin improved to 52.1%, up from 51.1% in Q2 2025 and 51.0% in Q3 2024, indicating enhanced operational efficiency [7][12] - The company achieved its 13th consecutive quarter of positive cash flow from continuing operations and 9th consecutive quarter of positive free cash flow, with net cash provided from continuing operations at $7.1 million [4][11][16] Financial Performance - GAAP net loss from continuing operations was $9.9 million, compared to a loss of $6.4 million in Q2 2025 and $15.8 million in Q3 2024 [7][13] - EBITDA from continuing operations was $14.3 million, down from $15.9 million in Q2 2025 but up from $9.7 million in Q3 2024 [7][14] - Adjusted EBITDA from continuing operations was $17.0 million, with an adjusted EBITDA margin of 26.1%, compared to 24.6% in Q2 2025 and 25.9% in Q3 2024 [7][14] Operational Highlights - The company maintained its leadership position in New Jersey, with four of its six stores ranking among the top ten in Pennsylvania and a 14.8% revenue increase in Maryland year-over-year [4][11] - The Apothecarium store in Phillipsburg was the top store in New Jersey, and the launch of a new preroll assortment led to a 32% increase in category sales [11] - The company is on track to exit the Michigan market by year-end 2025, with plans to divest substantially all Michigan assets [5][11] Strategic Developments - TerrAscend completed a $79 million non-dilutive refinancing of existing debt and has an additional uncommitted term loan facility of up to $35 million for strategic M&A [11][17] - The Board of Directors authorized a normal course issuer bid to repurchase up to $10 million of the company's common shares over a 12-month period [11] - Cash and cash equivalents stood at $36.6 million as of September 30, 2025, reflecting a strong balance sheet with no material debt maturities for several years [15][5]

Core Insights - Knight Therapeutics Inc. achieved record-high quarterly revenues, adjusted EBITDA, and adjusted EBITDA per share since inception, with increased financial guidance for 2025 [1][7][44] Financial Results - Revenues for Q3-25 were $121,548, an increase of $29,285 or 32% compared to Q3-24, driven by incremental revenues from the Paladin and Sumitomo Transactions and growth in key promoted products [6][12] - Adjusted revenues were $122,628, reflecting a 34% increase year-over-year [6][64] - Gross margin was $55,810 or 46% of revenues, down from 49% in the same period last year, impacted by hyperinflation and step-up expenses [6][16] - Operating income was $646, a significant decrease from $3,203 in Q3-24, while net loss was $3,791 compared to net income of $85 in the prior year [6][20] - Adjusted EBITDA reached $20,987, a 56% increase from the previous year, with adjusted EBITDA per share at $0.21, up 62% [6][64] Product Developments - Knight launched several products including Jornay PM™ in Canada, Minjuvi in Argentina, and Pemazyre in Brazil and Mexico [7][34][37] - The company expanded its partnership with Incyte for exclusive distribution rights of retifanlimab and axatilimab in Latin America [31] - Regulatory setbacks were noted for Tavalisse in Brazil and Qelbree in Canada, with appeals and responses planned [38][39] Corporate Developments - The company initiated a Normal Course Issuer Bid (NCIB) to purchase up to 3,000,000 common shares over the next 12 months [6][41] - Knight doubled its revolving credit facility to US$100 million, enhancing financial flexibility for future transactions [7][42] Financial Outlook - For fiscal 2025, Knight increased its revenue guidance to between $430 million to $440 million, up from $410 million to $420 million, with adjusted EBITDA expected to be between 13.5% to 14.5% of revenues [44]

Third Quarter Earnings Supplemental November 4, 2025 CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS & NON-GAAP MEASURES This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). All statements other than statements of historical fact are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial position, results of operations, plans, objectives, future per ...

Financial Performance - Q3 2025 - Net sales for Q3 2025 were $493.8 million, a 6.8% increase compared to $462.3 million in Q3 2024[12] - Non-GAAP earnings per diluted share for Q3 2025 were $2.08, a 10.1% increase compared to $1.89 in Q3 2024[12] - Adjusted EBITDA for Q3 2025 was $82.9 million, with adjusted EBITDA margins of 16.8%[12, 18] Financial Performance - YTD 2025 - Net sales for YTD 2025 reached $1.42 billion, a 1.8% increase compared to $1.3956 billion in YTD 2024[11, 12] - Non-GAAP earnings per diluted share for YTD 2025 were $5.37[11, 12] - Adjusted EBITDA for YTD 2025 was $227.4 million[11, 12] Leverage and Liquidity - The company's net debt stood at $703 million as of September 30, 2025[23] - The leverage ratio was 2.4x as of September 30, 2025, operating well within the bank's maximum permitted leverage of 4.0x[11, 23] - The company had cash and cash equivalents of $172 million[23] Sales Volume - Sales volumes increased by 3% year-over-year in Q3 2025, driven by new business wins across all regions[15]

Financial Performance - Aon achieved 7% organic revenue growth in Q3 2025, consistent with Q3 2024[8, 9] - Adjusted operating margin expanded by 170 basis points to 26.3%[8, 9, 15] - Adjusted earnings per share (EPS) grew by 12%[8, 9] - Free cash flow increased by 13% to $1.079 billion in Q3 2025[8, 9] Segment Performance - Commercial Risk Solutions and Reinsurance Solutions both experienced organic revenue growth of 7% and 8% respectively[10, 24] - Health Solutions saw organic revenue growth of 6%, while Wealth Solutions grew by 5%[10, 24] Capital Allocation - The company remains disciplined in capital allocation, balancing strategic investments with capital return to shareholders[8] - Capital return to shareholders included $161 million in dividends and $411 million in share repurchases in Q3 2025[19] Guidance and Outlook - Aon is on track to achieve its full-year 2025 financial commitments and expects to enter 2026 with strong momentum[8] - The company anticipates mid-single-digit or greater organic revenue growth for the full year 2025[12, 20]

Core Insights - CN reported strong financial results for Q3 2025, with a 6% increase in earnings and an operating ratio improvement of 170 basis points to 61.4% [5][6][19] - The company is focusing on productivity and has set a capital expenditure budget of C$2.8 billion for 2026, a reduction of nearly C$600 million from 2025 [2][5] - CN's net income for Q3 2025 was C$1,139 million, a 5% increase from the previous year, with diluted EPS rising to C$1.83, also a 6% increase [6][19] Financial Performance - Total revenues for Q3 2025 were C$4,165 million, up C$55 million or 1% from Q3 2024 [6][12] - Operating income increased by C$91 million or 6% to C$1,606 million [6][12] - Free cash flow for the first nine months of 2025 was C$2,341 million, a 14% increase from the same period in 2024 [6][27] Operational Metrics - Gross ton miles (GTMs) increased by 1% to 111,901 million, while revenue ton miles (RTMs) also rose by 1% to 57,188 million [6][12] - The company achieved a 2% improvement in fuel efficiency, consuming 0.833 US gallons of fuel per 1,000 GTMs [6][12] - Car velocity improved by 1% to 211 car miles per day, and train length increased by 3% to 8,049 feet [6][12] Shareholder Returns - CN repurchased close to 8 million shares for approximately C$1 billion during the quarter [5][12] - The Board of Directors approved a quarterly dividend of C$0.8875 per common share, payable on December 30, 2025 [7][12] Future Guidance - The company maintains its guidance for 2025, expecting mid-to-high single-digit adjusted diluted EPS growth [8][12] - CN is positioning itself to benefit from higher future volumes while enhancing long-term value for customers and shareholders [2][5]